<<

. 2
( 3 .)



>>

oiieeii?aaeiu [33]. A enneaaiaaiee Troglitazone In the Prevention Of
Diabetes Study (TRIPOD) n o?anoeai 1333 ?aiuei n aanoa-
O aieuiuo NA 2 oeia e iaoeaioia n IOA iaooi?iei
ainoiaa?ii oeo?oaao iieacaoaee ?e?iaiai iaiaia, ia- oeiiiui NA [46] ?a?ac 30 ianyoaa iaae?aaiey auei au-
ae?aaaony oiaiuoaiea eee noaaeeecaoey aana [34,35]. A yaeaii ainoiaa?iia nie?aiea ?enea NA 2 oeia ia 50%, a
oae?a aieaa aunieay noaiaiu nio?aiaiey ?–eeaoie a
enneaaiaaiee Diabetes Prevention Programm iieacaii,
?oi iaooi?iei i?eaiaeo e noaaeeuiiio nie?aie? aana ia a?oiia o?iaeeoaciia ii n?aaiaie? n a?oiiie ieaoaai.
2–3 ea. Ii oia?aiii nie?aao eiioaio?aoe? OA, aicii?ii, Aneaanoaea oiai, ?oi o?iaeeoacii ia ?aeiiaiaoaony en-
ca n?ao oiaiuoaiey niaa??aiey EIIII a nuai?ioea e?i- iieuciaaou a oneiaeyo aaiaoioiene?iinoe, aaiiia ennea-
ae, ?oi naycaii ni nie?aieai neioaca iineaaieo a ia?aie. aiaaiea i?aaiieaaaao aaeuiaeoaa eco?aiea i?aia?aoia
Ioia?aii iaaieuoia iiauoaiea EIAI, iaoneiaeaiiia aaiienoia ?aoaioi?ia, aeoeae?oaiuo i?ieeoa?aoi?ii
aeeyieai iaooi?ieia ia aeoeaiinou ia?aii?iie eeiacu ia?ienenii–? (PPAR–?).
[36], oioy a ?yaa ?aaio iiaiaiia aeeyiea ionoonoaoao [29].
Aeneeieaaiey
Ioia?aii, ?oi iaooi?iei i?eaiaeo e nie?aie? iannu oa-
ea o eeo n i?e?aieai, ii aac ia?ooaiee oaeaaiaiiai ia-
iaia (BIGPRO 1 e 1.2 (Biguanides and Prevention of Risk of Iaoaaiee?aneee neia?ii oa?aeoa?ecoaony iiauoa-
Obesity)) [37] e ia aeeyao ia eiioaio?aoe? eaioeia. Ioia- ieai OA, nie?aieai EIAI e EIIII [47]. Oaaee?aiea
?aii iiei?eoaeuiia aeeyiea iaooi?ieia ia nenoaio aa- aana aunooiaao a ?iee ioneiaiai oaeoi?a a ?acaeoee
iinoaca. Ia oiia iiiioa?aiee o iaoeaioia n/aac NA 2 oe- eeieaiuo ia?ooaiee. A enneaaiaaiee Second National
Health and Nutrition Examination Survey (NHANES II) auya-
ia iaae?aaeinu iiauoaiea oea?eiieeoe?aneie aeoeaii-
noe aneaanoaea nie?aiey eiioaio?aoee oea?eiiaaia, ii- eaia annioeaoey ia?ao oaaee?aieai EIO e iiauoaie-
auoaiey oeaiaaiai aeoeaaoi?a ieacieiiaaia e, ?oi aieaa ai OA ia 35–48%, nie?aieai EIAI ia 5–9% o ?aiuei.
aa?iyoii, cia?eoaeuiiai iiaaaeaiey aeoeaiinoe eiaeaeoi- Iaeaieaa aunieee iieacaoaeu iauee oieanoa?ei/EIAI
?a aeoeaaoi?a ieacieiiaaia (EAI–1). A iaeioi?uo ennea- iaae?aaeny o ?aiuei a iinoiaiiiaoca, no?aaa?ueo
aiaaieyo iiaiaiuo aeeyiee ia iaae?aaeinu [38,39]. i?e?aieai. Oaaee?aiea EIO o io??ei (NHANES II) an-
Aaiiua i aeeyiee iaooi?ieia ia AA e?aeia i?ioe- nioee?iaaii n oaaee?aieai OA ia 62–118% e nie?aie-

454 13, 7, 2005
oOaeCOa a aOaAeeiCe
Intervention Trial (VA–HIT) aaioea?icee, ianiio?y ia ionoo-
ai EIAI ia 7–15%.
Iiieii iaiaaeeaiaioiciie oa?aiee, ?yao iaoeaioia noaea aeeyiey ia EIIII, i?eaiaee e nie?aie? OA, iiau-
o?aaoaony iacia?aiea eaea?noaaiiuo n?aanoa. Iniiaiu- oaie? EIAI, oiaiuoaie? ?anoiou ano?a?aaiinoe eiiae-
ie i?aia?aoaie, eniieucoaiuie aey ea?aiey iaoaai- ie?iaaiiuo na?aa?ii–ninoaenouo niauoee [52]. A ennea-
ee?aneiai neia?iia, yaey?ony noaoeiu, oea?aou e aiaaiee Bezafibrate Intervention Program (BIP) aacaoea?ao
ieaoei (ieeioeiiaay eeneioa), eioi?ua iacia?a?ony n ieacuaae aieaa au?a?aiiia aeeyiea ia EIAI ii n?aaia-
o?aoii eiie?aoiie neooaoee. Iaiaoiaeii iiiieou, ?oi ie? n aaioea?iceeii a enneaaiaaiee VA–HIT. Ia auei
noaoeiu a iniiaiii i?eaiayo e nie?aie? EIII, a oae?a auyaeaii annioeaoee ia?ao oa?aieae aacaoea?aoii e
OA e iiaoo iiauoaou eiee?anoai EIAI. Oea?aou ieacu- nie?aieai na?aa?ii–ninoaenouo eiia?iuo oi?ae a ennea-
aa?o iaeneiaeuiia aeeyiea ia OA e yaey?ony i?aia?aoa- aiaaiee BIP. Ii anae aeaeiinoe nouanoaoao ianeieuei
ie auai?a a neo?aa aeia?eeieaaie?aneiai iaie?aaoeoa. aicii?iuo iauyniaiee. N?aaiee iieacaoaeu EIII o ia-
I?e ii?iaeuiuo iieacaoaeyo OA iie nie?a?o EIII, ia- oeaioia a enneaaiaaiee BIP ninoaaeye 148 ia/ae, oiaaa eae
iaei o iaoeaioia n aunieeie cia?aieyie iauaai oieanoa- a enneaaiaaiee VA–HIT 111 ia/ae. I?e?eiie iiaiaiuo
?eia e OA iiaoo eo (EIII) iiauoaou. Oea?aou niiniano- ?acee?ee, aa?iyoii, yaeyaony oi, ?oi a enneaaiaaiea
ao?o o?ainoi?iaoee EIIII a iaiaa aoa?iaaiiua EIII VA–HIT aee??aee aieuoaa eiee?anoai iaoeaioia n iaoa-
e ii n?aaiaie? ni noaoeiaie i?eaiayo e aieaa au?a?ai- aiee?aneei neia?iiii e NA, eioi?ua eo?oa ioaaoeee ia
iiio iiauoaie? EIAI. Ieaoei e ieeioeiiaay eeneioa oa?aie? oea?aoaie. Ia enee??aaony oae?a ?ieu neo?ay.
niinianoao?o oaaee?aie? EIAI e nie?aie? EIII e OA. Ai–ia?auo, a enneaaiaaiee VA–HIT auea auyaeaia anni-
Aey iiauoaiey EIAI i?aia?aoii auai?a yaeyaony iea- oeaoey ia?ao oa?aieae aaioea?iceeii e nie?aieai in-
oei. Eiiaeie?iaaiiay oa?aiey noaoeiia n oaiioea?aoii iiaiuo na?aa?ii–ninoaenouo niauoee o iaoeaioia n/aac
eee ieaoeiii ieacuaaao iiei?eoaeuiia aeeyiea ia ?ac- NA n aunieeie iieacaoaeyie einoeeia iaoiuae [53].
ee?iua eiiiiiaiou iaoaaiee?aneiai neia?iia. Ai–aoi?uo, aiaeec a iiaa?oiiao iaoeaioia n i?eciaeaie
Ianiio?y ia oi, ?oi noaoeiu yaey?ony i?aia?aoaie iaoaaiee?aneiai neia?iia e aunieeie enoiaiuie iiea-
auai?a aey nie?aiey EIII, iie ia ieacuaa?o aeeyiey caoaeyie OA ? 200 ia/ae a enneaaiaaiee BIP auyaee ainoi-
ia ana aniaeou eeieaiie o?eaau (EIIII, EIAI e OA), o aa?iia nie?aiea ?anoiou iaueo ia?ae?iuo eiia?iuo oi-
iaoeaioia n iaoaaiee?aneei neia?iiii ?anoi iaae?aa- ?ae [54]. A–o?aoueo, a enneaaiaaiee Diabetes Atherosclerosis
Intervention Study (DIAS) ioia?aeinu ainoiaa?iia oiaiu-
aony iinoiiiaeaeuiay aeia?eeieaaiey. Iaoeaioai n ia-
oaaiee?aneei neia?iiii ?aeiiaiaoaony nie?aou EIII oaiea ei?iia?iie iaoieiaee ii aaiiui aiaeia?aoee o
ai oaeaauo cia?aiee. A enneaaiaaiee Heart Protection iaoeaioia n NA 2 oeia ii n?aaiaie? n a?oiiie ieaoaai.
Study iiaoaa??aaia aunieay yooaeoeaiinou neiaanoa- Iao aaeiiai iiaiey ia yooaeoeaiinoe eiiaeie?i-
oeia a aica 40 ia o iaoeaioia n iiauoaiiui ?eneii ?ac- aaiiiai i?eiaiaiey oea?aoia e noaoeiia ii i?e?eia aic-
aeoey EAN eee aa yeaeaaeaioia ii n?aaiaie? n a?oiiie ii?iiai oaaee?aiey neaainoe e aiee a iuooao, aaaouae
ieaoaai. [48]. Ioia?aeinu ainoiaa?iia nie?aiea iauae e ?aaaiieieeco e nia?oe, ?oi iaae?aaaony i?e eiiaeia-
nia?oiinoe, ?enea EAN e einoeuoa a a?oiia aeoeaiie oa- oee aaioea?iceea n oa?eaanoaoeiii [55]. Ianiio?y ia io-
?aiee e a a?oiia iaoeaioia n NA, eioi?ua oa?aeoa?eci- noonoaea ?aoeeo aaiiuo i aeeyiee eiiaeie?iaaiiie oa?a-
aaeenu aieaa noa?oei aic?anoii e aieaa aunieie ?anoi- iee noaoeiaie e oea?aoaie ia eiia?iua oi?ee, caneo?e-
oie ano?a?aaiinoe EAN. Oa?aiey noaoeiaie iaania?eaa- aaao aieiaiey eiiaeiaoey noaoeia n oaiioea?aoii, iea-
ea ainoiaa?iia nie?aiea ?enea EAN e einoeuoa i?e e?- cuaa?uay iiei?eoaeuiia aeeyiea ia eeieaiue i?ioeeu.
auo cia?aieyo EIII [49]. A enneaaiaaiee Aey auyaeaiey iiei?eoaeuiuo e io?eoaoaeuiuo aniaeoia
Anglo–Scandinavian Cardiac Outcomes Trial–Lipid Lowering neiaanoaoeia a aica 10 ia/aaiu a ea?anoaa iiiioa?aiee
Arm (ASCOT–LLA) eco?aeinu aeeyiea aoi?aanoaoeia a eee a eiiaeiaoee n oaiioea?aoii 200 ia/aaiu Vegs n ni-
aica 10 ia/ae ia nie?aiea EIII e oiaiuoaiea oaoaeu- aao. auiieieee ?aiaiiece?iaaiiia ieaoaai–eiio?iee?o-
iiai e iaoaoaeuiiai EI o iaoeaioia 40–79 eao n AA e ia- aiia enneaaiaaiea n ia?ae?anoiui aecaeiii [56]. I?i-
iei ec oaeoi?ia ?enea (eo?aiea, aeia?o?ioey eaaiai ?a- aie?eoaeuiinou ea?aie oacu ninoaaeyea 3 ianyoa. Ia
eoai?ea, auyaeaiiua eciaiaiey ia YEA, aic?ano >54 eao, oiia neiaanoaoeia auei auyaeaii nie?aiea iauaai oi-
naiaeiue aiaiiac ?aiieo na?aa?ii–ninoaenouo caaiea- eanoa?eia ia 27%, iauaai aii–A ia 31%, EIII ia 28% e
aaiee, iee?i/iae?iaeuaoieio?ey, NA 2 oeia, caaieaaa- aii–A EIII ia 21%. I?e aiaaaeaiee oaiioea?aoa ia-
iea ia?eoa?e?aneeo ninoaia, io?neie iie, iauee oiea- ae?aaeinu aaeuiaeoaa nie?aiea eeiii?ioaeaia. Neiaa-
noa?ei/EIII > 5,9, aiaiiac oa?aa?iaaneoey?iiai niau- noaoei niinianoaiaae iaainoiaa?iiio oaaee?aie? EIAI
oey) [50]. Enneaaiaaiea auei inoaiiaeaii ain?i?ii ?a?ac (6%), aaeuiaeoaa iiauoaiea eioi?uo iaae?aaeinu i?e
3,3 aiaa ii i?e?eia au?a?aiiiai iiei?eoaeuiiai aeey- aiaaaeaiee e oa?aiee oaiioea?aoa (23%). Ia auei auya-
iey i?aia?aoa. A auoaoeacaiiie aica aoi?aanoaoei iea- eaii na?uaciuo ia?aeaoaeuiuo yaeaiee a a?oiia neiaa-
cuaae ainoiaa?iia iiei?eoaeuiia aeeyiea ia iinoi?ai- noaoeia e eiiaeie?iaaiiie oa?aiee. A enneaaiaaiee n
aeaeuiue iaoaaieeci eeiii?ioaeiia. o?anoeai 120 iaoeaioia n NA 2 oeia e aeia?eeieaaieae
I?e aiaeeca enneaaiaaiee, a eioi?uo i?eiaiyeenu eiiaeie?iaaiiia iacia?aiea aoi?aanoaoeia e oaiioea-
noaoeiu, ieacaeinu, ?oi i?ioaio iaoeaioia n iaoaaiee?a- ?aoa niinianoaiaaei oeo?oaie? eeieaiiai i?ioeey ?a-
neei neia?iiii e NA auoa oai, aaa ie?a enoiaiue n?aa- ?ac 24 iaaaee iaae?aaiey – nie?aie? OA ia 50%, EIII
iee iieacaoaeu EIII. Cia?eoaeuiia ?enei iaoeaioia n ia 46% e iiauoaie? EIAI ia 22% io enoiaiiai [57].
na?aa?ii–ninoaenouie caaieaaaieyie a enneaaiaaiee VA Ieaoei, iiieii iiei?eoaeuiiai aeeyiey ia eeiea-
oa?aeoa?eciaaeenu ieceeie iieacaoaeyie EIAI e EIII iue i?ioeeu, oaaee?eaaao i?iaoeoe? ae?eicu ia?aiu?,
[51]. A enneaaiaaiee Veterans Administration–High Density ?oi iioaioeaeuii iiauoaao o?iaaiu ae?eicu o iaoeaioia

455

13, 7, 2005
oOaeCOa a aOaAeeiCe
n iaoaaiee?aneei neia?iiii e ia?ooaiiie ae?eicie ia- aaaony o iaoeaioia iieiaiai aic?anoa n ii?iaeuiui
oiuae ai cia?aiee, oa?aeoa?iuo aey NA. Iiyoiio o iaoe- aanii oaea e naiaeiui aiaiiacii AA [67]. Auyaeaia
aioia n iieacaoaeyie ae?eicu iaoiuae 100–126 ia/ae aai acaeiinaycu ia?ao einoeeii?acenoaioiinou? e auniei
neaaoao iacia?aou n inoi?i?iinou?. O iaoeaioia n oi?i- ii?iaeuiuie o?iaiyie AA [68]. Yoi naeaaoaeunoaoao i
oei aeeeaie?aneei eiio?ieai aicii?ii iacia?aiea oii, ?oi einoeeii?acenoaioiinou yaeyaony iaiei ec oa-
n?aaieo aic ieaoeia a oi?iao n caiaaeaiiui aunaiai?- eoi?ia ?enea ?acaeoey AA. Nouanoaoao e aeuoa?iaoeaiay
aaieai i?aia?aoa [58]. Ieaoei o iaoeaioia n iaoaaiee?a- eiioaioey, niaeanii eioi?ie AA aaaao e iiyaeaie? ei-
neei neia?iiii ii?ao auou eniieuciaai a eiiaeiaoee n noeeii?acenoaioiinoe. Ieiei 50% iaoeaioia n AA eia-
a?oaeie i?aia?aoaie. A aaieiii neaiii enneaaiaaiee n ?o einoeeii?acenoaioiinou e aeia?einoeeiaie? [70,71].
o?anoeai 160 iaoeaioia n EAN, ieceeie iieacaoaeyie Iniiaiay ?ieu a yoii iaoaiecia i?eaaaony cae?uoe?
EIAI e ii?iaeuiuie EIII, iieo?a?ueo iaei ec 4–o ?a- iaeeeo eaieeey?ia n iaaaiaieai ninoaenoiai ?onea
?eiia oa?aiee (neiaanoaoei + ieaoei, aioeieneaaio, neaeaoiie ioneoeaoo?u. Nie?aiea e?iaioiea a neaeao-
neiaanoaoei + ieaoei+aioeieneaaio, ieaoaai) auei au- iuo iuooao iaoneiaeeaaao oiaiuoaiea ooeeecaoee
yaeaii aiaeia?aoe?aneia e eeeie?aneia oeo?oaiea iiea- eie ae?eicu, oi anou i?eaiaeo e ioiineoaeuiie einoee-
caoaeae a a?oiia iaoeaioia, iieo?a?ueo neiaanoaoei e ii?acenoaioiinoe iuoa?iie oeaie [72].
Iiauoaiea AA yaeyaony iacaaeneiui oaeoi?ii
ieaoei ia oiia 3–eaoiaai iaae?aaiey [59].
?enea ?acaeoey aoa?ineea?ica, a oae?a ii?ao niinia-
A?oa?eaeuiay aeia?oiiey noaiaaou a?oaei iaoaaiee?aneei ia?ooaieyi [73,74]. A
ianoiyuaa a?aiy nouanoao?o aaiiua i nayce iiauoai-
Eia?ueany aaiiua i oa?aeoa?a nayce ia?ao einoee- iiai niaa??aiey einoeeia n ?acaeoeai aoa?ineea?ica. O
ii?acenoaioiinou? e AA aanuia i?ioeai?a?eau. Nouano- yiiioaa onoaiiaeaia acaeiinaycu aeia?einoeeiaiee n
aoao i?aaiiei?aiea, ?oi iiauoaiiue oiion NIN yaeyao- aeia?o?eaeeoa?eaaieae, ni?aoa?uaeny n ieceei o?ia-
ny ia?ae?iui caaiii, iauaaeiy?uei einoeeii?ace- iai EIAI, e n eiioaio?aoeae iauaai oieanoa?eia e
noaioiinou e AA. A Tecumseh enneaaiaaiee iaae?aaee ia- EIII. E?iia oiai, ia?yao n acaeiinaycu? ia?ao o?ia-
oeaioia a aic?anoa 7, 20–22 e 30 eao. Ieacaeinu, ?oi o iai einoeeia e?iae iaoiuae, AA e iieacaoaeyie eeiea-
30–eaoieo iaoeaioia n AA, i?e?aieai, oaoeea?aeae e ei- iiai niaeo?a, auyaeaia acaeiinaycu ia?ao einoeeii?a-
noeeii?acenoaioiinou? a aic?anoa 7 eao iaae?aaeenu ii- cenoaioiinou? e ia?ooaieyie eiiiiiaioia nenoaiu aa-
auoaiea ?NN e AA, a a 20–eaoiai aic?anoa – ecauoi?iue iinoaca, a eiaiii – aeia?eiaaoeyoee e aeiioea?eiieeca.
aan. Neiiaoe?aneay aeia?aeoeaiinou i?aaoanoaoao eae Naycu ia?ao oaaee?aieai aana e o?iaiai AA ioia-
einoeeii?acenoaioiinoe, oae e iiauoaie? AA. O iaoeai- ?aaony a oaeii ?yaa enneaaiaaiee. A enneaaiaaiee
NHANES III a a?oiia iaoeaioia > 60 eao auyaeaia iiei-
oia n iiauoaiiui o?iaiai eaoaoieaieiia e?iae e ii?-
iaeuiui o?iaiai einoeeia ?a?ac 10 eao iaae?aaeinu ?eoaeuiay annioeaoey ia?ao iieacaoaeai EIO e ?an-
?acaeoea AA n iiauoaieai o?iaiy einoeeia [60,61]. Aic- oioie ano?a?aaiinoe AA [75]. Naycu ia?ao AA e iiau-
ii?iui iaoaieciii iiaiaiie acaeiinayce yaeyaony oaiiui EIO iaae?aaeanu a i?iniaeoeaiii enneaaiaa-
iee Nurses Health Study [76] e O?aieiaaineii ennea-
neiiaoe?aneay aacieiino?eeoey, eioi?ay, i?aiyonoaoy
aiaaiee [77]. ?anoioa ano?a?aaiinoe ? 2 na?aa?ii–ni-
aaaeaaoiiio e?iainiaa?aie? e o?ainii?oo ae?eicu a ia-
oaaiee?anee aeoeaiua neaeaoiua iuoa?iua eeaoee, nii- noaenouo oaeoi?ia ?enea iaae?aaaony o 56% io??ei,
nianoaoao ninoiyie? ioiineoaeuiie einoeeii?acenoaio- no?aaa?ueo i?e?aieai, e o 62,4% ?aiuei (O?aiei-
iinoe [62]. A enneaaiaaiee n o?anoeai cai?iauo aia?i- aaineia enneaaiaaiea) [78]. Ioiineoaeuiee ?ene ?acae-
aieuoaa auei ioia?aii, ?oi iiauoaiea AA yaeyaony i?a- oey EAN o io??ei n i?e?aieai e ? 3 oaeoi?aie ?enea
aeeoi?ii einoeeii?acenoaioiinoe e annioee?iaaii n ai- ii n?aaiaie? n iaoeaioaie aac oaeoi?ia ?enea ninoaa-
eaa aunieie ?NN e niaa??aieai eaoaoieaieiia [63]. Ia- eyao 2,07, a o ?aiuei n i?e?aieai – 10,9 (p<0,05). Oa-
iaei ?ya iaae?aaiee ia ?eaioiuo naeaaoaeunoaoao ia io- eei ia?acii, ii?ii aiai?eou i oii, ?oi ia?u, iai?aa-
noonoaee acaeiinayce ia?ao iiauoaiiui oiionii NIN, eaiiua ia nie?aiea eiee?anoaa ?e?iaie oeaie e ecau-
?acaeoeai AA e einoeeii?acenoaioiinou? [64]. oi?iiai aana, ea?a?o aa?io? ?ieu a nie?aiee na?aa?-
M. Modan i?aaiiei?ee, ?oi eiioaio?aoey einoeeia ii–ninoaenoiai ?enea eae ia eiaeaeaoaeuiii o?iaia,
naycaia n AA iacaaeneii io iaee?ey ia?ooaiey oiea- oae e a iauae iiioeyoee. I?e iaae?aaiee iaoeaioia a
?aioiinoe e ae?eica e i?e?aiey [65]. A aaiiuo acaeii- oa?aiea 16 eao a oiaa O?aieiaaineiai enneaaiaaiey
ioiioaieyo ea?a?o ?ieu iiauoaiea aeoeaiinoe neiia- ieacaeinu, ?oi nie?aiea aana ia 2,25 ea annioee?iaaii
oe?aneie ia?aiie nenoaiu [66], i?ieeoa?aoey aeaaei- ni nie?aieai eiee?anoaa oaeoi?ia ?enea eae o io??ei,
iuoa?iuo noaiie ninoaia, iiauoaiea ?aaani?aoee ia- oae e o ?aiuei [79]. AA yaeyaony iaiaa aa?iui i?aaee-
o?ey e eciaiaiea o?ainii?oa eaoeiiia. I?iniaeoeaiua oi?ii einoeeii?acenoaioiinoe ii n?aaiaie? n iiauoa-
enneaaiaaiey iieacaee, ?oi AA ?acaeaaaony ai?acai ?a- ieai OA e nie?aieai EIAI [80]. Iacia?aiea aeaou
ua o iaoeaioia n aeia?einoeeiaieae, ?ai o iaoeaioia n DASH (Dietary Approaches to Stop Hypertension), iniia-
ii?iaeuiui o?iaiai einoeeia [67]. I?e iaoa–aiaeeca iuie ?a?oaie eioi?ie yaeyaony ia?aie?aiea niee, oaa-
?acoeuoaoia ?yaa yieaaieieiae?aneeo enneaaiaaiee ee?aiea a ?aoeiia iaiuae e o?oeoia, i?iaoeoia n iec-
auea auyaeaia iiei?eoaeuiay ei??aeyoey ia?ao o?ia- eei niaa??aieai ?e?a, aiaaouo eaeeai e eaeuoeai, ya-
iai einoeeia iaoiuae e iaee?eai AA. Aeia?einoeeia- eyaony aa?iui aniaeoii oa?aiee AA [81].
iey ?anoi iaae?aaaony i?e nenoiee?aneie AA e ya- Iaaeeaiaioiciay oa?aiey AA o iaoeaioia n iaoa-
eyaony neeuiui i?aaeeoi?ii na?aa?ii–ninoaenoie aiee?aneei neia?iiii io?a?aia a iieiie aa?nee ?o-
nia?oiinoe [69]. Iiauoaiea einoeeia iaoiuae iaae?- eiaianoaa Iauaaeiaiiiai Iaoeiiaeuiiai eiieoaoa

456 13, 7, 2005
oOaeCOa a aOaAeeiCe
NOA ii i?ioeeaeoeea, aeaaiinoeea, ioaiea e ea?aie? i?aiu o?oaii iiooaaou, io?ii aeoaioe?iaaou aieiaiea
iiauoaiiiai AA (IIE 7, 2003). Iiieii ?aeiiaiaaoee iaoeaioia ia oii, ?oi aa?a iacia?eoaeuiia nie?aiea
ii iaiaaeeaiaioiciie oa?aiee, iano?aaaony ?ieu aana i?eaaaao e aeaaii?eyoiui iineaanoaeyi. Ooi?ia-
eAIO e aeieaoi?ia ?aoaioi?ia aiaeioaiceia (A?A) o iea aeeyiey iaooi?ieia e oeacieeaeaeiiia o iaoeai-
iaoeaioia n NA 2 oeia. A enneaaiaaiee HOPE (Heart oia n iaoaaiee?aneei neia?iiii o?aaoao i?iaaaaiey
Outcomes Prevention Evaluation trial) n o?anoeai 9297 aaeuiaeoeo enneaaiaaiee.
iaoeaioia aunieiai ?enea ? 55 eao n NA eee ninoae-
nouie ii?a?aieyie a ni?aoaiee n iaiei ec na?aa?-
aEUA?UU?
ii–ninoaenouo oaeoi?ia ?enea e ii?iaeuiie nenoiee-
1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,
?aneie ooieoeae auei auyaeaii ainoiaa?iia nie?a-
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third
iea ia?ae?iuo na?aa?ii–ninoaenouo oi?ae (EI, ei-
Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,
noeuo, na?aa?ii–ninoaenoay nia?ou) a a?oiia ?aiei?e- Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
ea ii n?aaiaie? n a?oiiie ieaoaai. Iiei?eoaeuiay final report. Circulation 106, 3143 3421(2002).
?ieu eAIO a i?aaoi?a?aaiee NA iaae?aaeanu a en- 2. Ridker PM. Buring JE, Cook N R, Rifai N. C–reacrive protein, the metabolic syndrome
and risk of incident cardiovascular events: an 8–year follow–up of 14, 719 initially healthy
neaaiaaiee ALLHAT (Antihypertesive and Lipid Lowering
american women. Circulation 107,391–397 (2003).
Treatment to Prevent Heart Attack Trial), n?aaieaa?uai
3. Mclaughlin T, Abbasi F, Cheal K et al. Use of metabolic markers to identify overweight
aeeyiea oei?oaeeaiia, eeceiii?eea e aieiaeieia o individuals who are insulin resistant. Ann. Intern. Med. 139, 802–809 (2003).
iaoeaioia ii?eeiai aic?anoa n AA, e a enneaaiaaiee 4. Anoop Misra, Naval K. Vikram. Insulin resistance syndrome (metabolic syndrome) and
LIFE (Losartan Intervention For End point reduction in Asian Indians. Current Science, 2002. Vol 83, No 12, p. 1483–1496.
5. Brotman Daniel J, MD, Girod John P, DO. The Metabolic syndrome: A tug–of–war with
hypertension), n?aaieaa?uai eica?oai e aeieaoi?u
no winner. Cleveland Clinic Journal of Medicine, 2002, Vol 69, Number 12, p 990–94.
?aoaioi?ia aiaeioaiceia [82]. Iaoeaioai aunieiai ?e-
6. George L. Bakris, MD. Optimal Management of Hypertention and Obesity in the
nea n iaoaaiee?aneei neia?iiii iieacaii iacia?aiea Metabolic Syndrome. A Monograph for continuing Medical Education Credit. 2001.
eAIO eee aeieaoi?ia ?aoaioi?ia aiaeioaiceia iaca- Illinois.
aeneii io o?iaiy AA, aneaanoaea eo iiei?eoaeuiiai 7. Ginsberg NH, Huang LS. The insulin resistance syndrome: impact on lipoprotein
metabolism and atherothrombosis. J Cardiovasc Risk. 2000; 7: 325–331.
aeeyiey ia iieacaoaee aeeeaiee.
8. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low–density lipoprotein par-
?–aeieaoi?u niinianoao?o nie?aie? na?aa?ii–ni-
ticles as a predictor of the risk of ischemic heart disease in men. Prospective results from
noaenoie caaieaaaaiinoe e nia?oiinoe o iaoeaioia n AA, the Quebec Cardiovascular Study. Circulation 1997; 95: 69–75.
aee??ay iaoeaioia n NA. Aieaa oiai, iie yaey?ony i?a- 9. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am
ia?aoaie auai?a o iaoeaioia n EAN. Aaiiua i?aia?aou J Cardiol. 1999; 83: 25F–29F
10. Reaven G, Laws A, eds. Insulin Resistance. The Metabolic Syndrome X. Totowa, NS:
iiaoo ieacuaaou aeeyiea ia oaeaaiaiue e eeieaiue ia-
Humana Press; 1999: 51–81.
iai. A enneaaiaaiee ARIC iaae?aaeanu annioeaoey oa-
11. Ford ES. Giles WH.DietzWH. Prevalence of the metabolic syndrome among US adults:
?aiee ?–aeieaoi?aie n iiauoaieai ?enea ?acaeoey NA. findings from the Third National Health and Nutrition Examination Survey. / Am. Med.
Oaeia aeeyiea ii?ii iauynieou nie?aieai e?iaioiea a Aaoc. 287, 356–359 (2002).
neaeaoiie ioneoeaoo?a, ?oi i?eaiaeo e oiaiuoaie? ca- 12. Bravata DM, Sanders L, Huang J et aL Efficacy and safety of low–carbohydrate diets:
a systematic review./ Am. Med. Assac. 289, 1837–1850 (2003).
oaaoa ae?eicu. Iaiaei n o?aoii oiai, ?oi a ?acaeoee ia-
13. Barnard RJ. Effects of life–style modification on serum lipids. Arch. Intern. Med. 151,
oaaiee?aneiai neia?iia ia iineaai?? ?ieu ea?aao ae-
1389–1394 (1991).
oeaaoey neiiaoe?aneie ia?aiie nenoaiu, iacia?aiea 14. Ornish D BS, Scherwin LW, Billings JH et aL Can lifestyle changes reverse coronary
aaiiuo i?aia?aoia ii?ao auou iaoiaaiaoe?anee ii?aa- heart disease? The Lifestyle Heart Trial. Lancet 336, 129–133 (1990).
aaiiui. A ianoiyuaa a?aiy nouanoao?o i?aia?aou n 15. Krauss Rtvf, Eckel RH, Howard B et ai AHA Dietary Guidelines: revision 2000: a state-
aunieie ?1–naeaeoeaiinoiinou?, oaeea eae iaoai?ieie, ment for healthcare professionals from the Nutrition Committee of the American Heart
Association. Circulation 102, 2284–2299 (2000).
aenii?ieie, iaaeaieie. Iineaaiee iaeaaaao i?aiu
16. Expert Panel on the identification and treatment of overweight and obesity in adults.
aa?iui aiiieieoaeuiui i?aeiouanoaii – noeioee?oao Executive summary of the clinical guidelines on the identification, evaluation and treat-
au?aaioeo yiaiaaiiiai ieneaa acioa – iiuiiai aaciae- ment of overweight and obesity in adults. At*. Intern. Med. 158. 1855–1867 (1998).
eaoaoi?a, iiyoiio iaaeaieie ii?ii n?eoaou iaiei ec 17. Bonow RO, Eckel RH. Diet, obesity and cardiovascular risk. N. Engl.J. Med. 348,
iaeaieaa i?aaii?oeoaeuiuo ?–aeieaoi?ia aey ea?aiey 2057–2058 (2003).
18. Samaha FF, Iqbal N, Seshadri P et aL A low–carbohydrate as compared with a low–fat
iaoeaioia n iaoaaiee?aneei neia?iiii.
diet in severe obesity. N. Engl. J. Med. 348, 2074–2081 (2003).
Iaoeaioai n 10%–iui ?eneii na?aa?ii–ninoaenouo 19. Foster GD, Wyatt HR, Hill JO et aL A randomized trial of a low–carbohydrate diet for
niauoee a iineaao?uea 10 eao iieacaii iacia?aiea obesity. N. Engt. ]. Med. 348, 2082–2090 (2003).
aoaoeenaeeoeeiaie eeneiou eee eiiaeie?iaaiiie oa- 20. Brehm BJ, Seeley RJ, Daniels SR, D’Alessio DA A randomized trial comparing a
very–low–carbohydrate diet and a calorie–restricted low–fat diet on body weight and car-
?aiee aoaoeenaeeoeeiaie eeneioie e aeie?eaaiieii.
diovascular risk factors in healthy women. / Clin. EndocrinoL Memo. 88, 1617–1623
Iaoeaiou n iaoaaiee?aneei neia?iiii, eae i?aaeei,
(2003).
eia?o aunieee ?ene na?aa?ii–ninoaenouo inei?iaiee, 21. Koertge J, Wcidner G, Elliott–Eller M ft at. Improvement in medical risk factors and
iiyoiio ei ?aeiiaiaiaaia aoaoeenaeeoeeiaay eeneioa quality of life in women and men with coronary artery disease in the Multicenter Lifestyle
a ieceie aica (81 ia). A enneaaiaaiee Physicians Health Demonstration Project. Am.]. CardioL 91. 1316–1322 (2003)
22. Pan X, Li G, Hu Y et ai Effects of diet and exercise in preventing NIDDM in people with
Study auyaeaii, ?oi aoaoeenaeeoeeiaay eeneioa ieacu-
impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20,
aaao aieaa au?a?aiiia aeeyiea o iaoeaioia n auniee-
537–544 (1997).
ie iieacaoaeyie N?A a ioee?ea io iaoeaioia aac ii- 23. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2
aiaiiai iiauoaiey (oaae. 3). diabetes with lifestyle intervention or metformin. N. EngiJ. Med. 346, 393–403 (2002).
Oaeei ia?acii, anai iaoeaioai n iaoaaiee?aneei 24. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus
by changes in lifestyle among subjects with impaired glucose tolerance/ N. Engl.J.Med.
neia?iiii iaiaoiaeii aaaaou ?aeiiaiaaoee ii ecia-
344, 1343–1350 (2001)
iaie? ia?aca ?ecie. Ianiio?y ia oi, ?oi iaoeaioai
25. Katzmarzyk PT, Leon AS, Wilmore JH et.al. Targeting the metabolic syndrome with
oOaeCOa a aOaAeeiCe
exercise: evidencefrom the HERITAGE Family Study. Med.Sci.Sports Exerc. 35, 1703–9 Care, 1993; 16: 621–629.
(2003) 39. Velazquez EM, Mendoza SG. et al. Metformin therapy is associated with a decrease in
26. Anderssen SA, Hjermann I, Urdal P, Torjesen PA, Holme I. Improved carbohydrate plasma plasminogen activator inhibitor–1, lipoprotein(a) and immunoreactive insulin lev-
metabolism after physical training and dietary intervention in individuals with the els in patients with the polycystic ovary syndrome. Metabolism, 1997; 46 (4): 454–457.
‘atherothrombogenic syndrome’ Oslo Diet and Exercise Study (ODES). A randomized 40. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with met-
trial. J.Intern.Med. 240, 203–9 (1996) formin reduces both blood pressure and metabolic risk factors. J Intern. Med., 1991;
27. Katzel LI, Bleecker ER, Colman EG, Rogus EM, Sorkin JD, Goldberg AP. Effects of 229: 181–7.
weight loss vs. Aerobic exercise training on risk factors for coronary disease in healthy, 41. Snorgaard O, Koeber L, Carlsen J. The effect of metformin on blood pressure and

<<

. 2
( 3 .)



>>